Gout is one of the most common inflammatory arthritis diseases, affecting 8.3 million adults in the U.S.1 It’s also one of the most preventable and treatable diseases, but only 32–58% of patients receive adequate gout treatment, indicating significant room for improvement of care.2
Also by this Author
For this reason, the ACR supported a group that developed several electronic clinical quality measures (eCQMs) that aim to close this gap. These measures give rheumatologists the chance to measure their performance in key areas of gout care, including gout care management, management of urate-lowering therapy, management of patients on urate-lowering therapy, serum urate monitoring and management, allopurinol-specific considerations and gout flare prophylaxis.
“These quality measures are shining a light on gout to show the quality of care being provide to patients with gout and how patients are doing to help us improve patient outcomes,” says John FitzGerald, MD, PhD, interim chief of the division of rheumatology at Ronald Reagan UCLA Medical Center, Los Angeles. As a leader in gout research, Dr. FitzGerald led the ACR group’s work to shape these eCQMs and coauthored a paper outlining the development of these measures.2